AIM ImmunoTech Inc. — Director's Dealing 2018

May 18, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2018-05-16

Reporting Person: MITCHELL WILLIAM M (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-05-16	Options to buy Common Stock	$0.3	A	152053	Acquired	2028-05-16	Common Stock (152053)	Direct
2018-05-16	Options to buy Common Stock	$0.3	A	100000	Acquired	2028-05-16	Common Stock (100000)	Direct

Footnotes

F1: This option is being issued to senior management for a voluntary 100% deferral of Directors fees.

F2: This option was awarded by the Board of Directors for serving as chairman of various committees.